Short-term efficacy of vedolizumab in patients with inflammatory bowel disease in real-life settings in Bosnia and Herzegovina

Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), necessitates effective management strategies. This study aims to evaluate the real-world efficacy of vedolizumab, a newer biological therapy, in treating IBD in Bosnia and Herzegovina. A retrospect...

Full description

Bibliographic Details
Published in:	Biomolecules & Biomedicine
Main Authors:	Nermin Salkić, Mirela Bašić Denjagić, Nađa Zubčević, Renata Tamburić, Azra Husić Selimović, Emil Babić, Milenko Bevanda, Aida Saray, Predrag Jovanović, Zoran Tošić, Aleksandar Dobrovoljski, Tatjana Barać
Format:	Article
Language:	English
Published:	Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2024-04-01
Subjects:	Inflammatory bowel disease (IBD) vedolizumab Crohn's disease (CD) ulcerative colitis (UC) real-world efficacy
Online Access:	https://www.bjbms.org/ojs/index.php/bjbms/article/view/10433

Similar Items

The effectiveness of vedolizumab in advanced therapy-experienced ulcerative colitis patients: Real world data from the Inflammatory Bowel Disease of the Middle East (IBD-ME) Registry group
by: Nahla Azzam, et al.
Published: (2025-01-01)

The Effects of the Biological Agents Infliximab, Vedolizumab, and Ustekinumab on Intestinal Anastomosis: An Experimental Study in Rats
by: Alexandra Menni, et al.
Published: (2025-04-01)

Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study
by: Merve Sivridaş, et al.
Published: (2023-03-01)

Real-World Safety of Vedolizumab in Inflammatory Bowel Disease: A Retrospective Cohort Study Supported by FAERS Signal Analysis
by: Bojana Milašinović, et al.
Published: (2025-07-01)

The significance of individual patient characteristics in a cohort of patients with inflammatory bowel disease treated with vedolizumab
by: Nadža Zubčević, et al.
Published: (2025-02-01)

Acute Chest Pain as an Infusion Reaction to Vedolizumab
by: Asaf Levartovsky, et al.
Published: (2022-06-01)

Histological Hallmarks of Mucosal Healing in Inflammatory Bowel Diseases in the Era of Monoclonal Antibodies Therapy: New Insights and Perspectives
by: Gerardo Cazzato, et al.
Published: (2021-08-01)

Efficacy and Safety of Natalizumab and Vedolizumab in the Treatment of Crohn’s Disease: A Systematic Review and Meta-Analysis
by: Ni Putu Sri Indrani Remitha, et al.
Published: (2025-09-01)

Comparison of the Effectiveness of Vedolizumab and Ustekinumab in Patients with Ulcerative Colitis: A Real-World Retrospective Study
by: Kei Nomura, et al.
Published: (2024-09-01)

A real-world study of vedolizumab versus infliximab in patients with moderate to severe ulcerative colitis
by: MENG Ruiping, et al.
Published: (2024-06-01)

Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis
by: Dart RJ, et al.
Published: (2017-03-01)

Vedolizumab in the treatment of inflammatory bowel diseases: whom and how?
by: A. O. Golovenko, et al.
Published: (2018-10-01)

Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience
by: Vlasta Oršić Frič, et al.
Published: (2023-02-01)

A STUDY ON CLINICAL PROFILE OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
by: Sadiqul Islam, et al.
Published: (2016-09-01)

Colonic Lung Cancer Metastasis in Vedolizumab-Treated Immune Checkpoint Inhibitor Colitis
by: Sean S. Davis, et al.
Published: (2020-07-01)

Segundo Consenso Mexicano de terapia biológica y moléculas pequeñas en enfermedad inflamatoria intestinal
by: J.K. Yamamoto-Furusho, et al.
Published: (2021-01-01)

Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naïve or anti-TNF-exposed Crohn's disease: a multicenter cohort studyResearch in context
by: Hongsheng Yang, et al.
Published: (2023-12-01)

Vedolizumab treatment in a patient with X-linked agammaglobulinemia, is it safe and efficient?
by: Şükrü Çekiç, et al.
Published: (2019-12-01)

Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study
by: Jeong Yeon Kim, et al.
Published: (2020-03-01)

Efficacy and Safety of Vedolizumab with Glucocorticoids vs Infliximabin Severe Ulcerative Colitis: A Retrospective Study
by: Zhang C, et al.
Published: (2025-06-01)

Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis
by: Keiichi Haga, et al.
Published: (2022-10-01)

Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review
by: Shengbo Fang, et al.
Published: (2022-04-01)

Adherence to Recommended Immunization Schedules in Patients with Inflammatory Bowel Disease on Biologics and Small Molecule Therapies
by: Mohammad Shehab, et al.
Published: (2023-09-01)

Inflammatory bowel disease evolution in the past two decades: a chronological multinational studyResearch in context
by: Pezhman Alavinejad, et al.
Published: (2024-04-01)

Vedolizumab–steroid combination therapy improves long-term prognosis in patients with ulcerative colitis
by: Yosuke Yamada, et al.
Published: (2025-04-01)

Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study
by: Laura Mühl, et al.
Published: (2021-01-01)

Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A
by: Holger Schäffler, et al.
Published: (2017-12-01)

Efficacy and safety of vedolizumab in elderly and younger patients with moderate-to-severe ulcerative colitis: a retrospective real-world study in China
by: Hao Zhang, et al.
Published: (2025-07-01)

Live-attenuated vaccination in patients with inflammatory bowel disease while continuing or after elective switch to vedolizumab
by: Hisashi Shiga, et al.
Published: (2024-07-01)

Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
by: Hamzah Abu-Sbeih, et al.
Published: (2018-12-01)

Vedolizumab combined with surgical resection successfully treated perforating Crohn’s disease with peritoneal space to rectal and vaginal fistulas: a case report
by: Meng-Wu Chung, et al.
Published: (2021-07-01)

Co-Administration of Proton Pump Inhibitors May Negatively Affect the Outcome in Inflammatory Bowel Disease Treated with Vedolizumab
by: Kata Szemes, et al.
Published: (2024-01-01)

Cost effective and reliable cell based ELISA as an alternative method of flow cytometry for assessment of binding activity of Vedolizumab
by: Swati Shalini, et al.
Published: (2023-02-01)

Ulcerative colitis successfully treated with vedolizumab in the presence of comorbid opportunistic infections: a case report
by: Yusuke Oki, et al.
Published: (2023-05-01)

OXIDATIVE STRESS AND INFLAMMATORY BOWEL DISEASE IN PEDIATRICS
by: M. Panayotova
Published: (2023-12-01)

The effect of smoking in inflammatory bowel disease outcomes
by: Basil A. Alzahrani, et al.
Published: (2024-06-01)

Artificial intelligence: A new tool in the pathologist's armamentarium for the diagnosis of IBD
by: Anna Lucia Cannarozzi, et al.
Published: (2024-12-01)

The PTPN22 C1858T (R620W) functional polymorphism in inflammatory bowel disease
by: Younes Zaid, et al.
Published: (2018-11-01)

Association between vedolizumab and risk of clostridium difficile infection in patients with ulcerative colitis: A systematic review and meta-analysis
by: Maha Alghamdi, et al.
Published: (2024-11-01)

Myopenia and body fat distribution in hospitalized ulcerative colitis patients: correlations with clinical characteristics and response to vedolizumab
by: Wei Wei, et al.
Published: (2024-12-01)